OC-0063: Real-time in-vivo dosimetry in HDR prostate brachytherapy  by Mason, J. et al.
ESTRO 35 2016                                                                                                                                                    S27 
______________________________________________________________________________________________________ 
biological imaging to target an ablative dose at known 
regions of significant tumour burden and a lower, therapeutic 
dose to low-risk regions. We describe our methods for 
defining target volume and prescription dose. 
 
Material and Methods: To demonstrate how tumour 
characteristics may be extracted from multi-parametric MRI 
(mpMRI) to inform the previously validated biological 
model(1), 21 patients underwent in vivo mpMRI prior to 
radical prostatectomy. Co-registration of histology and 
imaging data using rigid and deformable registration was 
validated by matching feature points and annotated zonal 
regions. Automated methods for defining tumour location, 
tumour cell density (TCD) and Gleason Score (GS) in histology 
were developed to provide high resolution ground truth 
data(2,3). Similarly, using ground truth histology data, 
machine learning methods have been developed and tested 
to predict tumour location in mpMRI. Further developments 
are underway to predict TCD, GS and hypoxia in mpMRI to 
build a multi-level voxel map defining tumour location and 
characteristics to inform the biological treatment planning 
model. 
 
Results: Co-registration of the in-vivo mpMRI with histology 
was achieved with an overall mean estimated error of 3.3 




An ensemble-based supervised classification algorithm, 
trained on textural image features, demonstrates a highly 
sensitive method for automated tumour delineation in high 
resolution histology images(2). Colour deconvolution and the 
use of a radial symmetry transform provides measures of cell 
density, shown to highly correlate with an expert pathologist 
markup of tumour location(3). A Gaussian-kernel support 
vector machine demonstrated a tumour location predictive 
accuracy of >80% with potential for significant improvement 
using Bayesian methods to incorporate neighbourhood 
information. Similar statistical methods have demonstrated 
potential for mpMRI parameter/pharmacokinetic maps to be 
correlated with tumour characteristics including TCD, GS and 
hypoxia. Whilst imaging methods for hypoxia exist, providing 
reliable, high spatial resolution ground truth data remains 
challenging. 
 
Conclusion: A novel approach to focal brachytherapy 
planning has been developed that incorporates mpMRI 
parameter/pharmacokinetic maps to inform a biological 
model and an inverse optimisation algorithm to maximise 
tumour control probability and minimise dose to organs at 
risk in prostate brachytherapy. The model can be equally 
applied to low and high dose rate brachytherapy, and 
possibly EBRT with high precision treatment delivery 
techniques. 1) Haworth, A. et al. Brachytherapy. 12, 628-36, 
(2013). 2) DiFranco, D. et al., Proc. SPIE 9420 (2015). 3) 
Reynolds, H. et al.. Proc. SPIE 90410S (2014). 
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Purpose or Objective: A High-Dose-Rate Brachytherapy 
(HDR-BT) boost combined with external beam radiotherapy 
(EBRT) produced excellent long term outcome and is an 
alternative for escalated EBRT (>72 Gy) for low and 
intermediate risk prostate cancer (PC) patients. The question 
remains whether the use of HDR-BT results in lower 
complication rates for equal tumour control. The aim of this 
study was to compare HDR-BT/EBRT combined to EBRT-only 
in terms of long-term patient-reported toxicity and 
oncological outcome for low and intermediate risk PC 
patients. 
 
Material and Methods: Between 2000 and 2007 low and 
intermediate risk PC patients (n=231) were treated (stage 
T1b-T2a, G≤7, iPSA≤17) with a HDR -BT boost (3x6 Gy) 
combined with EBRT (25x1.8 Gy). Patients with a maximum 
prostate volume of 120 cc and a PSA, T-stage, and Gleason in 
the same range were selected (68 Gy: n=83, 78 Gy: n=74) 
from the Dutch randomized dose-escalation study (1997-
2003). At least 1 follow-up questionnaire had to be 
completed. Genitourinary (GU) and gastrointestinal (GI) 
toxicity symptoms were prospectively assessed using same 
questionnaires in the period 1-7y years post-treatment. 
Prevalence of long term GU and GI symptoms were calculated 
with intervals of 1 year and compared between treatment 
groups (chi-square test). Biochemical failure free survival 
(BFFS) using the Phoenix definition (stratified for Gleason 
score) was calculated and compared (log-rank test). 
 
Results: Median follow up was 8.8y for both 68 Gy and 78 Gy 
patients, and 6.8y for HDR-BT/EBRT. Median age was 69y and 
68y, respectively. In general, post-treatment GU complaints 
were comparable between groups (dysuria, nocturia, day 
frequency, incontinence). Rectal blood loss was significantly 
lower for HDR-BT compared to 78 Gy, from the first year of 
follow-up and onwards (p<0.001). Rectal discomfort 
(pain/cramps) was significantly lower at 3y follow-up 
(p<0.01). Rectal incontinence showed lower rates as well, 
but these were not significant (p=0.08). Differences in stool 
frequency ≥ 4 were small and not significant. BFFS rates at 7y 
were 79%, 90%, and 96% (68 Gy, 78 Gy, HDR-BT) for Gleason 
<7 and 43%, 75%, and 91% for Gleason 7. BFFS was 
significantly higher in both the HDR-BT and 78 Gy group 
compared to 68 Gy (p=<0.001 and p=0.034 respectively), the 
difference between HDR-BT and 78 Gy was not significant 
(p=0.11).  
 
Conclusion: HDR-BT/EBRT is associated with significantly 
lower long-term GI toxicity compared to escalated EBRT-only 
(78 Gy) with a favorably comparable 7 years tumor control. 
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Purpose or Objective: Implement routine in-vivo dosimetry 
in HDR prostate brachytherapy and develop error detection 
thresholds for real-time treatment monitoring. 
 
S28                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
Material and Methods: In vivo dosimetry was performed for 
40 HDR prostate brachytherapy patients treated with single 
fractions of 15Gy (boost) or 19Gy (monotherapy). Treatments 
were planned using intra-operative trans-rectal ultrasound 
(TRUS) and for in-vivo dosimetry, an additional needle was 
inserted centrally in the prostate gland and dose measured 
using a MOSFET. MOSFET measurements were compared to 
predicted readings based on exported treatment planning 
system (TPS) data, per-needle and for total plan dose. To 
assess impact of needle movement between planning TRUS 
and treatment, TRUS images were acquired immediately 
after treatment for 20 patients. To assess impact of 
heterogeneities (for example steel needles) on the dose at 
the MOSFET position Monte Carlo (MC) simulations of 
treatment plans were performed for 10 patients. A 
retrospective investigation of thresholds for real-time error 
detection was based on per-needle and total plan uncertainty 
analysis. Uncertainties included MOSFET 
calibration/commissioning results, source calibration, TPS, 
relative source/ MOSFET position and MOSFET reading 
reproducibility. 
 
Results: The mean measured total plan reading was 6.6% 
lower than predicted (range +5.1% to -15.2%). Plan 
reconstruction on post-treatment TRUS showed mean 
reduction in dose at the MOSFET position of 1.8% due to 
needle movement. MC simulations showed that 
heterogeneities caused a mean dose reduction at the MOSFET 
position of 1.6%. Uncertainty estimates varied between 
individual treatment plans, for example the uncertainty is 
higher if the MOSFET is close to a heavily weighted source 
position. Assuming a source/MOSFET position uncertainty of 
1mm, total plan dose uncertainty (k=2) ranged from 10.6% to 
17.0% and per needle dose uncertainty (k=2) ranged from 
18.2% to 110% (mean 31.0%). Retrospectively applying these 
uncertainty estimates as error detection thresholds resulted 
in 1 out of 40 plans and 5% of needles being outside the error 
detection threshold. The figure shows an example for one 
patient of predicted versus measured reading for each needle 
with the k=2 uncertainty illustrated by error bars.
 
 
Conclusion: In vivo measurements of dose during HDR 
prostate brachytherapy treatment delivery show good 
agreement with TPS predictions within measurement 
uncertainties, providing reassurance in the accuracy of dose 
delivery. Thresholds for real-time in vivo error detection 
using this measurement technique should be calculated on an 
individual plan basis but would still be likely to generate 
some false errors, with the main limitation of the 
measurement technique being that dose is only measured at 
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Purpose or Objective: Localized recurrent prostate cancer 
after primary radiotherapy can be curatively treated using 
salvage, including Iodine-125 brachytherapy (BT). Selection 
of patients for salvage is hampered by a lack of knowledge on 
predictive factors for cancer control, particularly in salvage 
BT. The aim of this study was to develop and internally 
validate a prediction model for biochemical failure (BF) after 
salvage I-125-BT using the largest cohort to date in order to 
aid patient selection in the future.  
 
Material and Methods: Patients with a clinically localized 
prostate cancer recurrence who were treated with a whole-
gland salvage I-125 implantation were retrospectively 
analyzed. Patients were treated in two centers in the 
Netherlands. Multivariable Cox-regression was performed to 
assess the predictive value of clinically relevant tumor-, 
patient- and biochemical parameters on BF, which was 
defined according to the Phoenix-definition (PSA-nadir+2 
ng/ml). Missing data was handled by multiple imputation (20 
datasets). The model’s discriminatory ability was assessed 
with Harrell’s C-statistic (concordance index). Internal 
validation was done using bootstrap resampling (using 2000 
resampled datasets). Goodness-of-fit of the final model was 
evaluated by visual inspection of calibration plots, after 
which individual survival was calculated for categories of the 
predictor variables from multivariable analysis. All analyses 
were performed using the recently published TRIPOD 
statement. 
 
Results: Sixty-two whole-gland salvage I-125-BT patients 
were identified. After median follow-up of 25 (range 0-120) 
months, 43 patients developed BF. In multivariable analysis, 
disease-free survival interval (DFSI) after primary therapy and 
pre-salvage prostate–specific antigen doubling time (PSADT) 
were predictors of BF; corrected hazard ratio (HR) 0.99 (95% 
confidence interval [CI]: 0.98-0.997 [p=0.01]) and 0.94 
(95%CI: 0.90-0.99 [p=0.01]), respectively. Calibration plots 
demonstrated accurate predictive ability up to 36 months. 
The adjusted C-statistic was 0.71. Of patients with a 
PSADT>30 months and DFSI>60 months, >70% remained free 
of recurrence until 3 years. With every 12 months increase in 
DFSI, PSADT can decrease with 3 months to obtain the same 
survival proportion (Figure 1).  
 
